Patents by Inventor Andreas Reichel

Andreas Reichel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level, and a non-transitory computer readable medium
    Patent number: 11877869
    Abstract: The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 23, 2024
    Assignee: ROCHE DIABETES CARE, INC.
    Inventors: Andreas Reichel, Tobias Wiesner, Bernd Steiger
  • METHOD AND SYSTEM FOR DETERMINING A CARBOHYDRATE INTAKE EVENT FROM GLUCOSE MONITORING DATA INDICATIVE OF A GLUCOSE LEVEL, AND A NON-TRANSITORY COMPUTER READABLE MEDIUM
    Publication number: 20190216405
    Abstract: The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 18, 2019
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Andreas Reichel, Tobias Wiesner, Bernd Steiger
  • NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS
    Publication number: 20110124680
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: February 2, 2011
    Publication date: May 26, 2011
    Inventors: Rolf BOHLMANN, Martin Haberey, Andreas Huth, Stuart James Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Patent number: 7902229
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Patent number: 7601748
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: October 13, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
  • 17?-alkyl-17?-oxy-estratrienes and intermediate products for their production, use of the 17?-alkyl-17?-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
    Patent number: 7538100
    Abstract: The invention relates to 17?-alkyl-17?-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17?-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17?-alkyl-17?-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17?-alkyl-17?-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 26, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Rolf Bohlmann, Nikolaus Heinrich, Rolf Jautelat, Jorg Kroll, Orlin Petrov, Andreas Reichel, Jens Hoffmann, Rosemarie Lichtner
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Publication number: 20070021481
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Application
    Filed: August 9, 2006
    Publication date: January 25, 2007
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Patent number: 7138421
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: November 21, 2006
    Assignee: Schring Aktiengesellschaft
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
  • Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Publication number: 20060116380
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: November 3, 2005
    Publication date: June 1, 2006
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • 17?-ALKYL-17?-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17?-ALKYL-17?-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS
    Patent number: 7018994
    Abstract: The invention relates to 17?-alkyl-17?-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17?-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17?-alkyl-17?-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17?-alkyl-17?-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: March 28, 2006
    Assignee: Schering AG
    Inventors: Rolf Bohlmann, Nikolaus Heinrich, Rolf Jautelat, Jorg Kroll, Orlin Petrov, Andreas Reichel, Jens Hoffmann, Rosemarie Lichtner
  • 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
    Publication number: 20060009436
    Abstract: The invention relates to 17?-alkyl-17?-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17?-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17?-alkyl-17?-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17?-alkyl-17?-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.
    Type: Application
    Filed: July 26, 2005
    Publication date: January 12, 2006
    Inventors: Rolf Bohlmann, Nikolaus Heinrich, Rolf Jautelat, Jorg Kroll, Orlin Petrov, Andreas Reichel, Jens Hoffmann, Rosemarie Lichtner
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Publication number: 20050159468
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Application
    Filed: May 10, 2004
    Publication date: July 21, 2005
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
  • Piperazine derivatives that destabilize androgen receptors
    Patent number: 6861432
    Abstract: This invention relates to new piperazine derivatives of general formula I, in which V, W, n, R, R?, i, j, Y and Z have the meaning that is indicated in the description. The compounds according to the invention are distinguished by a diazacycloalkane substituent. They have at their disposal a special action with respect to the action that destabilizes the androgen receptor and can be used, for example, for treating prostrate cancer.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: March 1, 2005
    Assignee: Schering Aktiengesellschaft
    Inventors: Arwed Cleve, Christoph Huwe, Volker Schulze, Helmut Morack, Dieter Zopf, Jens Hoffmann, Andreas Reichel
  • Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally
    Publication number: 20040223983
    Abstract: The invention relates to pharmaceutical preparations that contain at least one emulsifier, at least one auxiliary emulsifier and/or solvent as well as at least one lipid, characterized in that the mass ratio of emulsifier to auxiliary emulsifier and/or solvent (Smix) is 1:1 to 9:1 and the total lipid proportion is >0% (m/m), whereby this preparation at least partially inhibits at least one intestinal enzyme and/or at least one intestinal efflux system. These preparations can be used to increase the bioavailability of pharmaceutical substances that are lipophilic and/or substrates of intestinal metabolizing enzymes and/or intestinal efflux systems, especially steroids.
    Type: Application
    Filed: October 7, 2003
    Publication date: November 11, 2004
    Inventors: Philip Lienau, Thomas Backensfeld, Andreas Reichel, Tanja Jung
  • Piperazine derivatives that destabilize androgen receptors
    Publication number: 20040009969
    Abstract: This invention relates to new piperazine derivatives of general formula I, 1
    Type: Application
    Filed: November 22, 2002
    Publication date: January 15, 2004
    Applicant: Schering AG
    Inventors: Arwed Cleve, Christoph Huwe, Volker Schulze, Helmut Morack, Dieter Zopf, Jens Hoffmann, Andreas Reichel
  • 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
    Publication number: 20030191099
    Abstract: The invention relates to 17&agr;-alkyl-17&bgr;-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17&bgr;-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17&agr;-alkyl-17&bgr;-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17&agr;-alkyl-17&bgr;-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.
    Type: Application
    Filed: November 27, 2002
    Publication date: October 9, 2003
    Applicant: Schering AG
    Inventors: Rolf Bohlmann, Nikolaus Heinrich, Rolf Jautelat, Jorg Kroll, Orlin Petrov, Andreas Reichel, Jens Hoffmann, Rosemarie Lichtner